Amerigen Pharmaceuticals Inc. and Stason Pharmaceuticals Inc. Oct. 18 announced they have entered into a collaboration agreement to develop generic oral oncology products.
Under the terms of the agreement, Stason will use its specialized containment facilities and formulation expertise to develop and manufacture products for Amerigen to commercialize in the United States and other territories.
Stason received an up-front fee and is eligible for additional product-specific development milestones, plus manufacturing revenues and royalties on any commercialized products, the companies said. Amerigen is based in East Brunswick, N.J., and Stason is based in Irvine, Calif.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.